证券代码：600201 证券简称：生物股份 公告编号：临 2025-038 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP， 参与本次互动交流，活动时间为 2025 年 7 月 11 日（周五） 16:00-18:00。届时 公司高管将在线就公司 2024 年度业绩、公司治理、发展战略、经营状况、融资 计划、股权激励和可持续发展等投资者关心的问题，与投资者进行沟通与交流， 欢迎广大投资者踊跃参与！ 特此公告。 金宇生物技术股份有限公司 董 事 会 二〇二五年七月十日 金宇生物技术股份有限公司 关于参加内蒙古辖区上市公司 2025 年投资者 网上集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 为进一步加强与投资者的互动交流，金宇生物技术股份有限公司（以下简 称 "公司"）将参加由内蒙古证监局、内蒙古自治区上市公司协会与深圳市全景网 络有限公司联合举办的"2025 年内蒙古辖区上市公司投资者集体接待日活 ...

关于子公司取得新兽药注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据国家《兽药管理条例》和《兽药注册办法》规定，经国家农业农村部审 查，批准金宇生物技术股份有限公司（以下简称"公司"）全资子公司扬州优邦 生物药品有限公司（以下简称"扬州优邦"）及其他单位联合研制的鸡新城疫、禽 流感（H9 亚型）、禽腺病毒病（I 群，4 型）三联灭活疫苗（La Sota 株+WF 株+rHx 株）为新兽药，详情如下： 一、新兽药产品基本情况 新兽药名称：鸡新城疫、禽流感（H9 亚型）、禽腺病毒病（I 群，4 型）三 联灭活疫苗（La Sota 株+WF 株+rHx 株） 注册分类：三类 新兽药注册证书号：(2025)新兽药证字68号 研制单位：扬州优邦生物药品有限公司、苏州沃美生物有限公司、哈药集团 生物疫苗有限公司、肇庆大华农生物药品有限公司、四川农业大学 证券代码：600201 证券简称：生物股份 公告编号：临 2025-039 金宇生物技术股份有限公司 贮藏与有效期：2～8℃保存，有效期为 18 个月。 二、新兽药产品 ...

Core Insights - The strategic partnership between Oushiman and Givaudan aims to integrate their strengths in the active ingredients sector, focusing on innovative development and application in cosmetics [1][2][6] - Oushiman has 58 years of experience in the Chinese market, with a strong emphasis on consumer-centered research and innovation, while Givaudan is recognized as an authority in active beauty ingredients and biotechnology innovation [2][4] - The collaboration is expected to enhance Oushiman's research capabilities and drive the internationalization of "pearl technology" and "precise solutions for Eastern skin" [2][6][7] Company Strengths - Oushiman has established a robust research framework, integrating data science, life sciences, and sustainable chemistry to drive innovation in pearl technology [4][5] - The company has developed a comprehensive research ecosystem, collaborating with top universities and research institutions, and has made significant contributions to industry standards and academic publications [5] - Oushiman's research achievements include 151 national invention patents and the establishment of the "Deqing Pearl System" as a global agricultural cultural heritage [5] Industry Trends - The beauty industry is undergoing a transformation driven by technology, with a focus on sustainable innovation and consumer safety [2][6] - The partnership signifies a convergence of Eastern and Western scientific approaches, aiming to redefine beauty industry standards and enhance the global research network for Eastern skin types [6][7] - The collaboration is positioned to create more effective, safe, and sustainable skincare solutions for global consumers, marking a new era in scientific advancements in the beauty sector [7]

Core Insights - The biopharmaceutical industry in Hohhot is experiencing rapid growth, driven by private enterprises and strategic initiatives focused on technological innovation and industrial chain enhancement [1][6] - Hohhot aims to establish itself as a leading hub for green biopharmaceuticals in Northern China, leveraging its industrial advantages to accelerate the transformation and commercialization of new technologies [6] Group 1: Industry Development - Hohhot is cultivating six major industrial clusters with a focus on biopharmaceuticals, achieving significant milestones such as the successful implementation of the world's first mRNA vaccine and intelligent manufacturing projects [1] - The city has over 60 biopharmaceutical companies, 143 innovation platforms, and 117 research institutions, with a projected industry output value of 20.25 billion yuan in 2024, accounting for approximately 7.9% of the city's industrial output [3] Group 2: Technological Innovation - Companies like Jinyu Biotechnology have pioneered technologies in large-scale cell culture and vaccine quality standards, contributing to advancements in vaccine development and production [1][4] - Innovative packaging technologies for fermentation agents and the development of vaccines such as the Brucella vaccine highlight the ongoing technological breakthroughs within the industry [2] Group 3: Collaborative Ecosystem - Hohhot has established a multi-level collaborative innovation ecosystem involving government, industry, academia, and research institutions, focusing on key technologies in animal vaccine production [4] - Partnerships between enterprises and academic institutions have led to significant advancements, such as the establishment of the largest lactic acid bacteria resource bank and successful technology transfers [4] Group 4: Policy Support - The local government has introduced various policies to support high-quality development in the biopharmaceutical sector, including financial incentives totaling 14 million yuan for innovation platforms and vaccine projects [5]

Group 1 - The core viewpoint indicates that the pig price is expected to maintain a central level above 15 yuan/kg in 2025 due to limited supply growth and cautious breeding practices [1][2] - The industry is experiencing a supply gap, with a notable increase in piglet losses due to a virus mutation, which is expected to drive up pig prices in Q3 2025 [1] - Recent government policies aim to regulate the pig industry, including measures to curb low-price competition and promote the orderly exit of outdated production capacity [1][2] Group 2 - The pig price is under significant downward pressure in H2 2025, but multiple government policies are expected to support price increases and alleviate CPI pressure [2] - The overall investment logic in the pig sector is improving due to supply contraction and macroeconomic catalysts, suggesting a positive outlook for investment [2] - The CSI Livestock Breeding Index reflects the performance of listed companies involved in livestock feed, veterinary drugs, and breeding, with the top ten weighted stocks accounting for 65.27% of the index [2]

Group 1 - The company will hold its second extraordinary general meeting of shareholders in 2025 on July 18, 2025, at 14:30 [4][6][32] - The meeting will adopt a non-cumulative voting method for the election of one independent director from two candidates [2][28][35] - The voting will be conducted both on-site and through the Shanghai Stock Exchange's online voting system [7][8][9] Group 2 - The independent director candidates are Mr. Hu Qi and Ms. Dong Qiuhong, nominated by shareholders [20][22][28] - The company has received nominations from shareholders holding 7.57% and 1.01% of the shares respectively [20][22][28] - The election process will ensure that the candidate with the highest number of affirmative votes from attending shareholders will be elected [29][35][36]

Summary of Key Points Core Viewpoint - The company, Bio Co., Ltd. (生物股份), is undergoing significant changes in its stock repurchase plan and has faced inquiries from investors regarding its management and investment strategies. Group 1: Stock Performance and Trading Information - As of July 1, 2025, Bio Co., Ltd. closed at 7.97 yuan, down 0.62%, with a turnover rate of 2.25% and a trading volume of 251,800 shares, amounting to a total transaction value of 201 million yuan [1] - On the same day, the net outflow of main funds was 16.39 million yuan, accounting for 8.14% of the total transaction value, while retail investors saw a net inflow of 12.19 million yuan, representing 6.06% of the total transaction value [5][7] Group 2: Company Announcements and Shareholder Information - Following the 2024 annual equity distribution, the maximum repurchase price for shares has been adjusted from 10.01 yuan to 9.98 yuan per share, with a total repurchase fund ranging from 80 million to 160 million yuan [6] - The company plans to distribute a cash dividend of 0.3 yuan per 10 shares (including tax), with the record date set for June 25, 2025, and the ex-dividend date on June 26, 2025 [6] - The company has indicated that any significant matters will be disclosed in accordance with relevant regulations, addressing investor concerns about management efficiency and communication [3][4]

证券代码：600201 证券简称：生物股份 公告编号：临2025-037 金宇生物技术股份有限公司关于 以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 | 回购方案首次披露日 | 2024/10/31 | | --- | --- | | 回购方案实施期限 | 董事会审议通过后 12 个月 | | 预计回购金额 | 8,000 万元~16,000 万元 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 万股 1,538.33 | | 累计已回购股数占总股本比例 | 1.3731% | | 累计已回购金额 | 万元 10,555.22 | | 实际回购价格区间 | 6.37 元/股~7.30 元/股 | 截至 2025 年 6 月 30 日，公司通过上海证券交易所交易系统以集中竞价交易方 式累计回购公司股份 1,538.33 万股，占公司总股本的比例为 1.3731%，成交最高 价为 ...

Group 1 - The stock price of Bio Shares (600201) closed at 8.02 yuan on June 30, 2025, with an increase of 1.52% and a turnover rate of 2.96% [1] - On June 30, the net inflow of main funds into Bio Shares was 22.06 million yuan, accounting for 8.34% of the total transaction amount [2][4] - The company announced an adjustment to the maximum repurchase price of its shares to not exceed 9.98 yuan per share due to the implementation of the 2024 annual equity distribution [2][4] Group 2 - The company plans to use its own funds to repurchase shares through centralized bidding, with a total repurchase amount not less than 80 million yuan and not exceeding 160 million yuan [2] - The profit distribution plan for 2024 is to distribute a cash dividend of 0.3 yuan per 10 shares (including tax), with the ex-dividend date set for June 26, 2025 [2] - The adjusted maximum repurchase price is calculated as 9.98 yuan per share after considering the cash dividend [2]

Summary of Key Points Core Viewpoint - The company has adjusted the maximum repurchase price of its shares from RMB 10.01 per share to RMB 9.98 per share following the implementation of the 2024 annual equity distribution plan [1][2][3]. Group 1: Share Repurchase Overview - The company approved a share repurchase plan using its own funds, with a total repurchase amount between RMB 80 million and RMB 160 million, and the repurchase period starting from the board's approval date [1]. - The repurchase is intended for employee stock ownership plans or equity incentives [1]. Group 2: Reasons for Price Adjustment - The adjustment in the repurchase price is due to the cash dividend distribution of RMB 0.3 per 10 shares, which will be distributed to all shareholders [2]. - The company plans to maintain the per-share distribution ratio even if the total share capital changes before the equity distribution date [2]. Group 3: Calculation of Price Adjustment - The new maximum repurchase price is calculated as follows: (previous maximum price - cash dividend) + (new share price × change in circulating shares) ÷ (1 + change in circulating shares) [3]. - The cash dividend per share is approximately RMB 0.0295, leading to the adjusted maximum repurchase price of RMB 9.98 per share [3]. Group 4: Other Matters - Other aspects of the share repurchase plan remain unchanged, and the company will adhere to relevant regulations during the repurchase period [4].